An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs BI 1607 (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioInvent International
- 23 Jan 2025 New trial record